Nylander I, Terenius L H
Department of Pharmacology, Uppsala University, Sweden.
Neuropharmacology. 1987 Sep;26(9):1295-302. doi: 10.1016/0028-3908(87)90090-6.
Peptides derived from prodynorphin, dynorphin A and B, (Leu)-enkephalin and (Leu)enkephalyl-Arg, as well as substance P, were measured in substantia nigra, striatum and globus pallidus, after subacute (5 doses at 6 hr intervals) treatment of rats with a number of dopamine receptor agonists and antagonists. Drugs selective for the dopamine D1 and D2 receptors, respectively, as well as unselective drugs were used. In the substantia nigra, levels of immunoreactive dynorphin A and dynorphin B were increased after treatment with a D2-antagonist (sulpiride) and a D1-agonist (SKF 38393), while a D1-antagonist (SCH 23390) reduced levels. The mixed D1 and D2 antagonist cis-flupenthixol reduced only the level of dynorphin A. A corresponding increase of the levels of (Leu)enkephalin in the nigra was found after treatment with sulpiride. In contrast to dynorphin peptides, the levels of (Leu)enkephalyl-Arg were markedly increased after both D1- and D2 (LY 171555)-stimulation. Substance P tended to be reduced after D1-stimulation and treatment with all the dopamine antagonists; the reduction was significant with sulpiride and cis-flupenthixol. Levels of peptides in striatum and globus pallidus were generally affected in the same direction as levels in the nigra. The results in this study present further evidence that dopamine receptor agents affect dynorphin peptides and substance P, differentially. Effects on (Leu)enkephalin and (Leu)enkephalyl-Arg only partly paralleled the effects on levels of dynorphin. Thus, the D1 and D2 receptors differentially affect levels of different products of prodynorphin, that is, seem to affect certain steps of the processing of prodynorphin selectively.
在用多种多巴胺受体激动剂和拮抗剂对大鼠进行亚急性(每隔6小时注射5剂)治疗后,测定了黑质、纹状体和苍白球中源自前强啡肽、强啡肽A和B、亮氨酸脑啡肽和亮氨酸脑啡肽-精氨酸的肽类,以及P物质的含量。分别使用了对多巴胺D1和D2受体具有选择性的药物以及非选择性药物。在黑质中,用D2拮抗剂(舒必利)和D1激动剂(SKF 38393)治疗后,免疫反应性强啡肽A和强啡肽B的水平升高,而D1拮抗剂(SCH 23390)则降低了其水平。D1和D2混合拮抗剂顺式氟哌噻吨仅降低了强啡肽A的水平。用舒必利治疗后,发现黑质中亮氨酸脑啡肽的水平相应升高。与强啡肽肽类相反,D1和D2(LY 171555)刺激后,亮氨酸脑啡肽-精氨酸的水平均显著升高。D1刺激以及用所有多巴胺拮抗剂治疗后,P物质含量有降低趋势;舒必利和顺式氟哌噻吨治疗后降低显著。纹状体和苍白球中的肽类水平变化方向通常与黑质中的一致。本研究结果进一步证明,多巴胺受体药物对强啡肽肽类和P物质的影响存在差异。对亮氨酸脑啡肽和亮氨酸脑啡肽-精氨酸的影响仅部分与对强啡肽水平的影响平行。因此,D1和D2受体对前强啡肽不同产物的水平影响不同,即似乎选择性地影响前强啡肽加工过程的某些步骤。